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Stillbirth remains a major concern across the globe and in some high-resource
countries, such as the UK, efforts to reduce the rate have achieved only modest
reductions. One third of stillborn babies are small for gestational age (SGA) and these
pregnancies are also at risk of neonatal adverse outcomes and lifelong health
problems, especially when delivered preterm. Current UK clinical guidance advocates
regular monitoring and early term delivery of the SGA fetus however; the most
appropriate regimen for surveillance of these babies remains unclear and often leads
to increased intervention for a large number of these women. This pilot trial will
determine the feasibility of a large-scale trial refining the risk of adverse pregnancy
outcome in SGA pregnancies using biomarkers of placental function sFlt-1/PlGF,
identifying and intervening in only those deemed at highest risk of stillbirth.
Methods
PLANES is a randomised controlled feasibility study of women with an SGA fetus that
will be conducted at two tertiary care hospitals in the UK. Once identified on
ultrasound, women will be randomised into two groups in a 3:1 ratio in favour of sFlt-
1/PlGF ratio led management vs standard care. Women with an SGA fetus and a
normal sFlt-1/PlGF ratio will have a repeat ultrasound and sFlt-1/PlGF ratio every 2
weeks with planned birth delayed until 40 weeks. In those women with an SGA fetus
and an abnormal sFlt-1/PlGF ratio we will offer birth from 37 weeks, or sooner if there
are other concerning features on ultrasound. Women assigned to standard care will
have an sFlt-1/PlGF ratio taken but the results will be concealed from the clinical team
and the woman’s pregnancy will be managed as per the local NHS hospital policy. This
integrated mixed method study will also involve a health economic analysis and a
perspectives work package exploring trial feasibility through interviews and
questionnaires with participants, their partners and clinicians.
 
Discussion
Our aim is to determine feasibility through the assessment of our ability to recruit and
retain participants to the study. Results from this pilot study will inform the design of a
future large randomised controlled trial that will be adequately powered for adverse
pregnancy outcome. Such a study would provide the evidence needed to guide future
management of the SGA fetus.
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Response to Reviewers: Dear Editor-in-Chief,
We thank the reviewers for their insightful comments and accepting our alterations to
the manuscript. We thank you for your comment which we have addressed below and





Dear Authors. Thank you for responding to my suggestions. My only outstanding point
is that I would suggest should you go to a definitive trial that you do not restrict the
economic analysis to a health services perspective. There are important potential
opportunity costs for women in the experimental group and it would be useful to have
those factored in.
1.Many thanks for this helpful and valid suggestion. We will certainly keep this in mind
and take it into account should the study progresses to a definitive trial.
Editor's comments:
Please provide clear description of the feasibility outcomes along with the criteria that
will be used to determine success of feasibility.
2.Many thanks for this important observation and request. We have removed lines 234
– 246 in the original manuscript and replaced it with the following that should fulfil your
request (Page 10, lines 233 – 253).
The outcomes for the study have been separated into those that determine the
feasibility of a definitive trial and those that address whether the intervention might
have an effect on neonatal outcome or healthcare costs. Our group has had previous
successful experience employing this approach in the ReMIT2 study [63].
The feasibility outcomes are: number of eligible women at each site; the number of
women recruited; the number of women randomised; the number of women not
compliant with the intervention and the reasons for this; reasons for not participating
(patients may still consent to the perspectives work package who do not wish to
participate in the main study) and number of women lost to follow up. Women’s and
birth partners views on the approach to recruitment, including consent, decision
making and length, content of trial information materials and views on the sFlt-1/PlGF
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
test will also be gathered in the perspectives work package. Clinicians’ views on the
acceptability of a future trial, including potential barriers to recruitment, consent
decisions, trial procedures and clinician training needs via questionnaires and a focus
group or interview will be collected.
The proof of concept outcomes for mother include: gestation and frequency of
induction of labour or planned Caesarean; frequency of maternal hypertensive
disorders; intensive care admission or maternal death prior to discharge. The proof of
concept outcomes for the baby include: stillbirth; neonatal death; Apgar score at 5
minutes <7; umbilical artery pH <7.05; birthweight <10th centile; admission to neonatal
unit and length of stay; use of therapeutic cooling; length of stay in hospital and
duration of respiratory support.
Reference
63. Armstrong-Buisseret L, Mitchell E, Hepburn T, et al. Reduced fetal movement
intervention Trial-2 (ReMIT-2): protocol for a pilot randomised controlled trial of
standard care informed by the result of a placental growth factor (PlGF) blood test
versus standard care alone in women presenting with reduced fetal movement at or





Have you included a 'Declarations' section
in your manuscript including all of the
subheadings listed below and the relevant
information under each?









Click here for information on what should
be included under each heading.
Please use the 'Contact Us' link above if
you require further assistance
I confirm I have provided a complete 'Declarations' section in my manuscript
<b>Is this study a clinical
trial?</b><hr><i>A clinical trial is defined
by the World Health Organisation as ‘any
research study that prospectively assigns
human participants or groups of humans
to one or more health-related
interventions to evaluate the effects on
health outcomes’.</i>
Yes
We require registration of all clinical trials
that are reported in manuscripts submitted
to the journal. More information about trial
registration, including the trial registries
that currently meet all of the ICMJE
guidelines, can be found in the FAQ
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registration/</a>.<p>Please provide the
following information where
prompted:<hr>Enter the Trial Registration
Number:<br/>&emsp;as follow-up to
"<b>Is this study a clinical
trial?</b><hr><i>A clinical trial is defined
by the World Health Organisation as ‘any
research study that prospectively assigns
human participants or groups of humans
to one or more health-related
interventions to evaluate the effects on
health outcomes’.</i>"
Enter the name of the registry:
<br/>&emsp;as follow-up to "<b>Is this
study a clinical trial?</b><hr><i>A clinical
trial is defined by the World Health
Organisation as ‘any research study that
prospectively assigns human participants
or groups of humans to one or more
health-related interventions to evaluate
the effects on health outcomes’.</i>"
ISRCTN
Enter the URL of the trial registry record:
<br/>&emsp;as follow-up to "<b>Is this
study a clinical trial?</b><hr><i>A clinical
trial is defined by the World Health
Organisation as ‘any research study that
prospectively assigns human participants
or groups of humans to one or more
health-related interventions to evaluate
the effects on health outcomes’.</i>"
https://doi.org/10.1186/ISRCTN58254381
Enter the date that you registered your
trial (in mm/dd/yyyy format):
<br/>&emsp;as follow-up to "<b>Is this
study a clinical trial?</b><hr><i>A clinical
trial is defined by the World Health
Organisation as ‘any research study that
prospectively assigns human participants
or groups of humans to one or more
health-related interventions to evaluate
the effects on health outcomes’.</i>"
04-07-2019
Was your trial registered before the first
participant was enrolled? (i.e.
prospectively registered)   <br/>&emsp;as
follow-up to "<b>Is this study a clinical
trial?</b><hr><i>A clinical trial is defined
by the World Health Organisation as ‘any
research study that prospectively assigns
human participants or groups of humans
to one or more health-related
interventions to evaluate the effects on
health outcomes’.</i>"
Yes
Within your manuscript, have you also
included details of your trial registration at
the end of your abstract?
Name of the registry•
Trial registration number•
Date of registration•
URL of trial registry record•
Example: Trial registration: ISRCTN,
I confirm I have provided trial registration details at the end of the abstract




 as follow-up to "Was your trial
registered before the first participant was
enrolled? (i.e. prospectively registered) "
Does your study have ethical approval? Yes, and I have included the relevant documentation as an additional file
Has your study received funding? Yes, the funding is external and not industry funded, and I have included the relevant
documentation as an additional file
Has your study undergone full external
peer review as part of your funding
application?
 as follow-up to "Has your study
received funding?"
Yes
What stage of participant recruitment is
your study at?
Participant recruitment has not started
<b>Standards of reporting</b><br>
<br>
Pilot and Feasibility Studies advocates the
complete and transparent reporting of
research and methods. Authors are
required to append the appropriate
reporting guideline checklist to their
manuscript on submission, and peer
reviewers will be asked to refer to this
checklist when evaluating such studies.
Checklists are available for a number of







page</a></li> for further information.<br>
<br>
Please confirm you have appended to
your manuscript file the required reporting
guideline checklist (and relevant
extensions) and flow diagram for your
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13th April 2020 
Dear Editor-in-Chief,  
We wish to submit a study protocol entitled “The PLANES Study: A protocol for a randomised controlled 
feasibility study of the placental growth factor (PlGF) blood test informed care versus standard care 
alone for women with a small for gestational age fetus at or after 32+0 weeks gestation” for 
consideration by Pilot and Feasibility Studies. 
 
One third of stillborn babies are small for gestational age (SGA) and these pregnancies carry significantly 
higher risk of neonatal adverse outcomes and lifelong health problems, especially when delivered preterm. UK 
guidance currently advocates regular monitoring and early term delivery of the SGA fetus however; the most 
appropriate regimen for surveillance of these SGA babies remains unclear and often leads to increased 
intervention for a large number of women, impacting upon a women’s choice as well as increasing the burden 
on the health care system. This pilot trial will determine the feasibility of a definitive trial refining the risk of 
adverse pregnancy outcome in SGA pregnancies using biomarkers of placental function sFlt-1/PlGF, 
identifying and intervening in only those at highest risk of stillbirth. 
 
We believe that this manuscript is appropriate for publication by Pilot and Feasibility Studies because of its 
promotion of transparency within the reporting of clinical trials, focusing on all aspects, not merely significant 
findings or outcomes but that of the processes and methodology. 
We can confirm that there are no conflicts of interest to disclose and all authors have approved this 
manuscript. This work is original and has not been published elsewhere, nor is it currently under consideration 
for publication elsewhere. 
Please address all correspondence concerning this manuscript to a.sharp@liv.ac.uk 
Thank you for your consideration of this manuscript.  
Sincerely, 
 
Dr Andrew Sharp MBBS, MRCOG, PhD, BSc  
Senior Lecturer and Honorary Consultant in Obstetrics 
T 0151 795 9560 
F 0151 795 9599 
E asharp@liv.ac.uk 
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We thank the reviewers for their insightful comments and accepting our alteration to 
the manuscript. We thank you for your comment which we have addressed below 
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Reviewer 2: 
Dear Authors. Thank you for responding to my suggestions. My only outstanding 
point is that I would suggest should you go to a definitive trial that you do not restrict 
the economic analysis to a health services perspective. There are important potential 
opportunity costs for women in the experimental group and it would be useful to have 
those factored in. 
 
1. Many thanks for this helpful and valid suggestion. We will certainly keep 





Please provide clear description of the feasibility outcomes along with the criteria 
that will be used to determine success of feasibility. 
 
2. Many thanks for this important observation and request. We have 
removed lines 234 – 246 in the original manuscript and replaced it with 
the following that should fulfil your request (Page 10, lines 233 – 253).  
The outcomes for the study have been separated into those that 
determine the feasibility of a definitive trial and those that address 
whether the intervention might have an effect on neonatal outcome or 
healthcare costs. Our group has had previous successful experience 
employing this approach in the ReMIT2 study [63].   
The feasibility outcomes are: number of eligible women at each site; the 
number of women recruited; the number of women randomised; the 
number of women not compliant with the intervention and the reasons 
for this; reasons for not participating (patients may still consent to the 
perspectives work package who do not wish to participate in the main 
study) and number of women lost to follow up. Women’s and birth 
partners views on the approach to recruitment, including consent, 
decision making and length, content of trial information materials and 
views on the sFlt-1/PlGF test will also be gathered in the perspectives 
work package. Clinicians’ views on the acceptability of a future trial, 
including potential barriers to recruitment, consent decisions, trial 
procedures and clinician training needs via questionnaires and a focus 
group or interview will be collected.  
The proof of concept outcomes for mother include: gestation and 
frequency of induction of labour or planned Caesarean; frequency of 
maternal hypertensive disorders; intensive care admission or maternal 
death prior to discharge. The proof of concept outcomes for the baby 
include: stillbirth; neonatal death; Apgar score at 5 minutes <7; 
umbilical artery pH <7.05; birthweight <10th centile; admission to 
neonatal unit and length of stay; use of therapeutic cooling; length of 
stay in hospital and duration of respiratory support.  
 
Reference 
63.  Armstrong-Buisseret L, Mitchell E, Hepburn T, et al. Reduced fetal movement 
intervention Trial-2 (ReMIT-2): protocol for a pilot randomised controlled trial 
of standard care informed by the result of a placental growth factor (PlGF) 
blood test versus standard care alone in women presenting with reduced fetal 
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Stillbirth remains a major concern across the globe and in some high-resource countries, 30 
such as the UK, efforts to reduce the rate have achieved only modest reductions. One third 31 
of stillborn babies are small for gestational age (SGA) and these pregnancies are also at risk 32 
of neonatal adverse outcomes and lifelong health problems, especially when delivered 33 
preterm. Current UK clinical guidance advocates regular monitoring and early term delivery 34 
of the SGA fetus however; the most appropriate regimen for surveillance of these babies 35 
remains unclear and often leads to increased intervention for a large number of these 36 
women. This pilot trial will determine the feasibility of a large-scale trial refining the risk of 37 
adverse pregnancy outcome in SGA pregnancies using biomarkers of placental function 38 
sFlt-1/PlGF, identifying and intervening in only those deemed at highest risk of stillbirth. 39 
Methods 40 
PLANES is a randomised controlled feasibility study of women with an SGA fetus that will be 41 
conducted at two tertiary care hospitals in the UK. Once identified on ultrasound, women will 42 
be randomised into two groups in a 3:1 ratio in favour of sFlt-1/PlGF ratio led management 43 
vs standard care. Women with an SGA fetus and a normal sFlt-1/PlGF ratio will have a 44 
repeat ultrasound and sFlt-1/PlGF ratio every 2 weeks with planned birth delayed until 40 45 
weeks. In those women with an SGA fetus and an abnormal sFlt-1/PlGF ratio we will offer 46 
birth from 37 weeks, or sooner if there are other concerning features on ultrasound. Women 47 
assigned to standard care will have an sFlt-1/PlGF ratio taken but the results will be 48 
concealed from the clinical team and the woman’s pregnancy will be managed as per the 49 
local NHS hospital policy. This integrated mixed method study will also involve a health 50 
economic analysis and a perspectives work package exploring trial feasibility through 51 






































































Our aim is to determine feasibility through the assessment of our ability to recruit and retain 55 
participants to the study. Results from this pilot study will inform the design of a future large 56 
randomised controlled trial that will be adequately powered for adverse pregnancy outcome. 57 
Such a study would provide the evidence needed to guide future management of the SGA 58 
fetus. 59 
Trial Registration 60 
ISRCTN REFERENCE: 58254381. Registered on 4 July 2019. 61 
 62 
Key words  63 
Fetal Growth Restriction (FGR), Intrauterine Growth Restriction, Small for Gestational Age 64 
(SGA), Placenta, Placental Growth Factor, Soluble fms-like tyrosine kinase. 65 
 66 
Background 67 
The stillbirth rate within the United Kingdom (UK) remains one of the highest in high-68 
resource countries (3.87 per 1000 births) [1], but stillbirths remain rare at term (2.0 per 1000 69 
births) [2].  Historically strategies to prevent stillbirth have focused on the identification of risk 70 
factors in early pregnancy [3-9]. However, risk factors present at booking predict less than 71 
20% of all stillbirths [8]. Furthermore, 33% of stillbirths occur after 36+0 weeks, 85% prior to 72 
labour with the cause of death unknown in 39% [8]. A third of all stillbirths however are small 73 
for gestational age (SGA) and therefore targeted identification and intervention on the small 74 
fetus has become an attractive surrogate strategy to prevent subsequent stillbirth [8]. Even 75 




































































Ratio 7.0, 95% confidence interval 3.3–15.1) [10-12], neonatal adverse outcome [13] and 77 
potential life-long health risks [14,15].  78 
The standard approach advocated by The National Institute for Health and Care Excellence 79 
(NICE) for all pregnant women in the UK to identify the SGA fetus relies upon serial 80 
measurement of the maternal abdomen with a tape measure from 24 weeks to generate the 81 
symphysial fundal height (SFH) [16]. SGA is suspected when the SFH measurement is 82 
<10th centile or there is static growth over two measurements. SFH measurement in 83 
isolation has a sensitivity of 30-40% [18, 19] and with no randomised controlled studies of its 84 
effectiveness [20]. Therefore, confirmatory ultrasound assessment is required, with SGA 85 
commonly defined as an estimated fetal weight (EFW) <10th centile [4, 17, 18]. However, 86 
the increase in detection of SGA with ultrasound is limited, with up to 41% of SGA fetuses 87 
remaining undiagnosed and a false positive rate of up to 20% [19]. 88 
The Royal College of Obstetricians and Gynaecologists (RCOG) has produced guidance for 89 
the management of the SGA fetus [18] but the Cochrane Collaboration acknowledge that the 90 
most appropriate regimen for antenatal surveillance is unclear [20]. This guidance advocates 91 
that the SGA fetus should have growth assessed with ultrasound every 2 weeks with 92 
additional fetal blood flow (Doppler) assessments. Timing of delivery is based upon 93 
deterioration in fetal growth or feto-placental Doppler (<37 weeks) or when the pregnancy 94 
reaches 37+0 weeks’ gestation even if all other factors are normal [18]. Therefore, the UK 95 
national health service (NHS) currently has a system for the management of the SGA fetus 96 
and prevention of stillbirth based upon SFH and confirmatory ultrasound with delivery from 97 
37+0 weeks. This ‘one size fits all’ approach maintains a safety margin to prevent stillbirth 98 
but leads to an increase in interventions, such as induction of labour (IOL) [21]. IOL rates for 99 
SGA are increasing (3.0% in 2012 to 10.7% in 2016) with up to 40% of all labours now 100 
induced [22]. 101 
Our recent survey of UK obstetric units demonstrates that this is a UK-wide phenomenon 102 




































































increase over 5 years and 90% stating that in their opinion management of SGA had been a 104 
factor. This increased intervention and delivery of SGA fetuses at a late preterm or early 105 
term gestation, whilst well intentioned is not without concern. There is a substantial body of 106 
evidence showing that being born <39 weeks has an impact upon a child’s cognitive 107 
development and later academic achievement [23-26]. Furthermore, whilst overall numbers 108 
of affected children are low, the term SGA fetus has a cerebral palsy risk 5-7 times greater 109 
than normal birth weight babies [27, 28]. There is also an impact on women’s choice as to 110 
place and mode of birth, especially when in general the risk of stillbirth is low [29] with 111 
intervention potentially not required for all SGA fetuses. 112 
Rationale for study population  113 
The desire to reduce stillbirth is powerful but due to the relative infrequency of this outcome 114 
it currently leads to increased intervention for a large number of women, which impacts upon 115 
a women’s choice and increases the burden on the health care system. However, most 116 
importantly whilst small gains have been made in stillbirth reduction in the UK the goal of 117 
significantly reducing stillbirth remains distant. Not all national guidelines are as prescriptive 118 
on the management of SGA, recently reviewed by McCowan et al. [30]. Canadian [31] 119 
guidance suggests close monitoring of the fetal condition with ultrasound after 37 weeks but 120 
with no defined time to deliver. Irish [32], United States of America and New Zealand 121 
guidance [33] is also more flexible suggesting that in the presence of normal Doppler studies 122 
the SGA fetus can be left until 38-39 or 40 weeks respectively. Much of this evidence for lack 123 
of harm from delaying delivery comes from the DIGITAT study that showed no adverse 124 
effects from induction of labour vs delayed delivery [34], though this study was 125 
underpowered to offer unequivocal evidence regarding perinatal mortality or severe 126 
morbidity. Recently some reaction against early delivery for SGA in the absence of other risk 127 
factors has been observed with a recent UK study deferring delivery until 40 weeks if fetal 128 
assessment was normal [35]. However, in this study there was a single stillbirth in the 129 




































































We suggest a potential ‘middle ground’ would be to refine the risk of adverse pregnancy 131 
outcome in SGA pregnancies with biomarkers of placental function, namely the sFlt-1/PlGF 132 
ratio. We feel that this may help clinicians to differentiate the fetus that is constitutionally 133 
small from that which has a reduced growth velocity due to placental failure. Identifying the 134 
group at highest risk of stillbirth would reduce the number of interventions performed, and 135 
reduce the number of babies delivered early whilst maintaining a safety margin to prevent 136 
stillbirth. This would represent a more detailed monitoring system than any other nation 137 
currently advocates. It would also align with the recent Saving Babies Lives Care Bundle, 138 
which advocates individualised risk assessments of SGA pregnancies and deferring delivery 139 
to 39 weeks in those pregnancies with no high-risk features [36]. 140 
Justification for intervention and biomarkers 141 
The use of biomarkers to identify the fetus at risk of stillbirth has been highlighted as a 142 
priority by the RCOG [18] and the James Lind Alliance [37]. However, their low predictive 143 
accuracy in the first trimester has limited their use as a screening tool [3]. Recent advances 144 
in our understanding of which biomarkers are clinically relevant in late pregnancy has 145 
demonstrated that identification of placental disease potentially predisposing to stillbirth is 146 
possible [38]. Principal among the biomarkers currently available is placental growth factor 147 
(PlGF). This protein is produced by the placenta and identifiable in maternal blood from 12 148 
weeks [39]. Two commercially available platforms which measure PlGF (Alere®) [40] or 149 
PlGF relative to sFlt-1 (sFlt-1/PlGF ratio) (Roche®) [41] have been endorsed by NICE for the 150 
investigation of hypertension in pregnancy [42]. Whilst the majority of studies have focused 151 
on the ability of these tests to predict preeclampsia there is a significant amount of 152 
information on their ability to predict stillbirth and SGA. Abnormally low levels of PlGF in 153 
maternal plasma have been linked to preeclampsia [40, 43, 44], SGA [45, 46] and stillbirth 154 
[40, 47]. Furthermore, an abnormal PlGF appears to more than double adverse pregnancy 155 
outcome [48] and is associated with critical fetal growth restriction [49-53]. In a cohort of 156 




































































centile, apgar <7 at 5 mins, NICU admission and placental pathology [40, 54, 55]. Women 158 
with the lowest PlGF values were in addition much more likely to have a growth restricted 159 
fetus and abnormal Dopplers [40, 47]. In all published studies to date very few fetuses have 160 
been stillborn following a normal PlGF result [40, 47, 53, 59-60]. The ratio of PlGF to soluble 161 
FMS-like tyrosine kinase-1 (sFlt-1), which binds PlGF in the circulation, is increased in 162 
preeclampsia [41], fetal growth restriction [56] and stillbirth [57]. An abnormal sFlt-1/PlGF 163 
ratio of >38 is associated with an increased risk of SGA (21% vs 7%) [58]. The sFlt-1/PlGF 164 
ratio appears to be equally useful in determining outcome with almost no stillbirths when the 165 
ratio is normal [41, 57-60] (Table 1). A recent Cochrane Diagnostic Test Accuracy Review on 166 
the effectiveness of biomarkers to predict stillbirth [61] confirms that abnormal PlGF or sFlt-167 
1/PlGF ratio has a diagnostic odds ratio of 49.2 for subsequent stillbirth. Therefore, PlGF or 168 
sFlt-1/PlGF ratio appear to be effective in identifying the fetus that is SGA and more 169 
importantly, those fetuses that go on to be stillborn.  170 
Table 1: Stillbirths by normal and abnormal PlGF and sFlt-1/PlGF ratio 171 
Author Year 
Stillbirth  
normal PlGF  
Stillbirth  







Chappell 2013 0 7 - - 
Benton 2016 1 6 - - 
Ziesler 2016 - - 1 3 
Sovio 2017 - - 0 0 
Sharp (1) 2018 0 1 - - 
Sharp (2) 2018 0  35  0 35 
Navaratnam 2017 0 1 0 1 
Total 1 50 1 39 
 172 
Objective 173 
The PLANES study (Placental Growth Factor Led Management of the Small for Gestational 174 




































































1/PlGF ratio led management of women with an SGA fetus, 2) to assess the acceptability of 176 
such an approach to women and clinicians and 3) to explore the feasibility/acceptability of 177 
the study design.  178 
Results from this feasibility study will inform the design of a future large randomised 179 
controlled trial (RCT) powered for adverse pregnancy outcome. 180 
Methods/Design 181 
The PLANES study is a randomised controlled feasibility study of standard care versus sFlt-182 
1/PlGF ratio led management of pregnant women with an ultrasound diagnosis of an SGA 183 
fetus (defined as having an EFW < 10th percentile for gestation) at 32+0 to 37+6 weeks’ 184 
gestational age. The 10th centile will be defined by what is considered to be usual practice 185 
for each site, both sites in the pilot study use the customised GROW chart. This integrated 186 
mixed method study will also involve a health economic analysis and a perspectives work 187 
package exploring trial feasibility through interviews and questionnaires with randomised 188 
patients and their partners, as well as a clinician focus group and/or questionnaires and 189 
interviews. 190 
Participants 191 
Inclusion criteria are women with a singleton pregnancy; confirmed SGA fetus (EFW <10th 192 
centile on ultrasound within preceding 72 hours); normal umbilical artery Doppler (Pulsatility 193 
Index <95th centile); between 32+0 and 37+6 weeks of gestation; maternal age >16 years 194 
old and able to give written informed consent. Exclusion criteria are known or suspected 195 
structural/chromosomal fetal abnormalities, either absent or reversed end diastolic flow in 196 
the umbilical artery on Doppler study and severe maternal disease requiring urgent delivery. 197 
Participation in the perspectives work package follows the same criteria for participants, with 198 
the additional exclusion criteria of women who do not speak English. The flow of each 199 




































































Figure 1. PLANES Patient Flow Diagram 201 
Intervention 202 
Following randomisation women will be asked to provide a blood sample for assessment of 203 
sFlt-1/PlGF ratio, the result of which will be revealed (biomarker led) or concealed (standard 204 
care) from the attending clinical team.  205 
Within the revealed / biomarker led care group participants with a normal sFlt-1/PlGF ratio 206 
(≤38) will be advised that their risk of an adverse pregnancy outcome is low and will be 207 
offered delivery at 40+0 weeks gestation. Women will be offered further ultrasound and sFlt-208 
1/PlGF ratios every 2 weeks, to ensure that they do not become high risk, with the care 209 
pathway adjusted if necessary (see Figure 1).  Participants with an abnormal sFlt-1/PlGF 210 
ratio (>38) will be advised to attend for detailed ultrasound assessment by a fetal medicine 211 
expert within 72hrs of the abnormal result being known. This assessment will involve fetal 212 
biometry and Doppler of the Umbilical Artery (UA), Middle Cerebral Artery (MCA) and Ductus 213 
Venosus (DV). If Doppler studies are normal then delivery will be advised from 37+0 weeks 214 
[18]. If there is evidence of critical fetal compromise (absent end diastolic flow in the UA or 215 
absent a-wave in the DV) then delivery will be performed as soon as feasible. If fetal Doppler 216 
studies are borderline (brain sparing (MCA Pulsatility Index <5th centile) or increased 217 
resistance in UA or DV (Pulsatility Index >95th centile)), the Doppler will be repeated every 218 
72hrs and delivery will be offered between 36+0 and 37+0 weeks.  219 
Women assigned to the concealed / standard care pathway will have an sFlt-1/PlGF ratio 220 
taken but the result will be concealed from the clinical team with their pregnancy being 221 
managed as per the local NHS guideline with delivery from 37+0 weeks. 222 
In all cases women will receive cCTG on the same day as ultrasound assessment and a 223 
minimum of twice weekly. If at any point cCTG demonstrates a short-term variability (STV) 224 
<3.0ms then delivery should be planned [62]. If at any point the attending clinical team feels 225 




































































recorded on an intention to treat basis. Women who prefer not to be randomised into the 227 
PLANES study will be offered the opportunity to give blood for a sFlt-1/PlGF ratio test with 228 
the result being concealed and not used to guide clinical management. 229 
Outcome Measures 230 
This study will assess the feasibility of using a blood biomarker, sFlt-1/PlGF ratio, to safely 231 
refine the care pathway for the management of women with an SGA fetus from 32 weeks of 232 
pregnancy. Post Hoc analysis of sFlt-1 and PlGF individually will also be conducted. The 233 
outcomes for the study have been separated into those that determine the feasibility of a 234 
definitive trial and those that address whether the intervention might have an effect on 235 
neonatal outcome or healthcare costs. Our group has had previous successful experience 236 
employing this approach in the ReMIT-2 study [63].  237 
The feasibility outcomes are: number of eligible women at each site; the number of women 238 
recruited; the number of women randomised; the number of women not compliant with the 239 
intervention and the reasons for this; reasons for not participating (patients may still consent 240 
to the perspectives work package who do not wish to participate in the main study) and 241 
number of women lost to follow up. Women’s and birth partner’s views on the approach to 242 
recruitment, including consent, decision making and length, content of trial information 243 
materials and views on the sFlt-1/PlGF test will also be gathered in the perspectives work 244 
package. Clinicians’ views on the acceptability of a future trial, including potential barriers to 245 
recruitment, consent decisions, trial procedures and clinician training needs via 246 
questionnaires and a focus group or interview will be collected.  247 
The proof of concept outcomes for mother include: gestation and frequency of induction of 248 
labour or planned Caesarean; frequency of maternal hypertensive disorders; intensive care 249 
admission or maternal death prior to discharge. The proof of concept outcomes for the baby 250 
include: stillbirth; neonatal death; Apgar score at 5 minutes <7; umbilical artery pH <7.05; 251 
birthweight <10th centile; admission to neonatal unit and length of stay; use of therapeutic 252 




































































Sample Size and Recruitment 254 
As a feasibility study, success will be determined on the acceptability of the management 255 
approach for women and clinicians. Participants will be recruited directly from the fetal 256 
medicine, antenatal clinic or maternity assessment units at the nominated research sites. It is 257 
proposed that the study should expect to recruit in the region of 100 participants across two 258 
sites over a 12 month period.  This is a pragmatic figure which is based on the typical 259 
number of SGA patients seen per annum in large consultant led NHS units within the UK.  260 
Participants will remain in the study for a maximum of 8 weeks (from 32+0 weeks [earliest 261 
point of eligibility] to estimated due date (EDD)). The study will end when the last recruited 262 
woman / baby is discharged from hospital after birth (up to age 1 month uncorrected) or the 263 
baby has reached their EDD. 264 
Enrolment and Consent 265 
Prior to taking part in the study all women will have confirmation of their SGA status 266 
completed by their attending clinician based on an ultrasound scan performed within the 267 
preceding 72 hours. Once a potential participant has been identified (all eligibility criteria 268 
met) they will be invited to take part in the study and a member of the clinical research team 269 
at site will discuss this with them. At this point the woman and partner will receive written 270 
(PLANES patient information sheet (PIS)) and verbal information on the PLANES study, as 271 
well as an opportunity to ask questions and take any additional time required to consider 272 
taking part in the study.  All potential participants will be given a unique screening ID that will 273 
subsequently be used to detail the reasons for the continuation or discontinuation at the 274 
screening stage. Participants willing to proceed will be asked to sign the study-specific 275 
Informed Consent Form (ICF) and once written informed consent has been provided 276 
participants will be registered onto the study and randomised by the research midwife / 277 




































































The PLANES PIS will also include information regarding taking part in the perspective work 279 
package. If women are happy to take part in this, they will be asked to complete the relevant 280 
sections of the study ICF. Women who decline to take part in the main study will also be 281 
asked if they would like to take part in this perspective work package and these participants 282 
will be expected to complete the standard participant ICF, initialling only those boxes 283 
relevant to the perspective study. 284 
The research team are conscious that women may not feel that they should deviate from 285 
‘normal’ NHS care despite the more detailed assessments of fetal wellbeing PLANES have set 286 
in place. In order to increase the ability of this study to inform a future RCT powered to prevent 287 
stillbirth we will ask women who decline to be randomised whether they would consent to a 288 
single sFlt-1/PlGF ratio being taken and stored for processing only after the study has ended.  289 
In this way we may still gain valuable information about the ability of this test to predict 290 
clinically relevant pregnancy outcomes even if women do not wish to be randomised. 291 
The critical data in the PLANES study is derived from blood samples. Refusal to give the 292 
crucial blood sample at randomisation would result in significant compromise to the study. 293 
Therefore, any participant who does not provide this sample would need to be withdrawn 294 
from the study. Participants can refuse any further subsequent blood sample and remain in 295 
the study under the intention to treat principle.  296 
Randomisation 297 
As there is greater value in the outcomes and opinions of those women undergoing the 298 
intervention participants will be randomised to receive revealed (biomarker led) or concealed 299 
pathways in a ratio of 3:1. Patients will be randomised by authorised site staff using an 300 
electronic randomisation system, accessed by delegated site staff using a secure password 301 
protected website. The randomisation code list will be generated on the basis of randomly 302 
permuted blocks by a Liverpool Clinical Trials Unit (LCTU) statistician using the ‘ralloc’ 303 




































































of Liverpool will be responsible for designing and supporting the PLANES randomisation 305 
program. It is not possible to blind the participant, or their attending midwife or clinician, to their 306 
allocated pathway at randomisation as the sFlt-1/PIGF ratio taken in the biomarker-led 307 
pathway will inform further management. 308 
Trial Assessments and Procedures 309 
A prerequisite prior to randomisation of the participant into the PLANES study is a review of 310 
the participants medical and medication history; fetal assessments including computerised 311 
CTG and fetal ultrasound; and maternal observations including blood pressure, pulse and 312 
urinalysis. Once informed consent has been obtained, the participant will be asked to provide a 313 
blood sample for assessment of the sFlt-1/PlGF ratio. The participant will then be randomised 314 
to either the revealed or concealed pathway. At this time the patient will also complete an EQ-315 
5D-5L health questionnaire and those consented to the perspectives work package will 316 
undertake a questionnaire, and, with additional patient consent either face to face or 317 
telephone interviews.  318 
Continuing assessments will vary dependant on the participants care pathway within the study, 319 
those in the control/concealed pathway receiving standard care and assessments on adverse 320 
events and standard care outcomes will taking place at the end of study. Participants within the 321 
revealed/biomarker led pathway will undergo blood pressure, pulse, urinalysis, computerised 322 
CTG and fetal ultrasound assessment as well as repeat sampling for sFlt-1/PlGF ratio as 323 
detailed below dependent on previous sFlt-1/PlGF ratio results and doppler studies. In all 324 
cases women will receive cCTG on the same day as ultrasound assessment and a minimum 325 
of twice weekly. Further assessments will take place after delivery and before discharge from 326 
hospital and this will include a repeat EQ-5D-5L health questionnaire, childbirth experience 327 
questionnaire and recording of delivery outcomes, and following this in the postnatal period, 328 




































































Clinicians at site at the end of the study will be asked to participate in focus groups, and for 330 
those who are unable to attend, online questionnaires and interviews will also be 331 
undertaken. 332 
Figure 2. Schedule of Study Related Assessments/Procedures 333 
Adverse Event Reporting 334 
All adverse events for this study will be recorded at each study visit, the condition of each 335 
participant monitored throughout the study until one month postnatal. The intervention to 336 
which participants are randomised to as part of this study provides additional care to that 337 
which is usually provided as part of local standard care and therefore large numbers of 338 
serious adverse events are not anticipated. SAE to be reported are that of intrauterine fetal 339 
death (stillbirth), maternal death and neonatal death, all of which are also pre specified 340 
outcomes for the study. Less serious adverse events (preterm delivery, pre-eclampsia, 341 
caesarean section, admission to neonatal unit) are exempt from immediate safety reporting 342 
due to the anticipation of these in SGA pregnancies - unless a causal relationship to the 343 
study design is suspected. 344 
sFlt-1/PlGF ratio blood tests 345 
The sFlt-1/PlGF ratio, will be used to guide intervention in the study, Roche® have agreed to 346 
provide the sFlt-1/PlGF ratio kits for no cost. Blood samples relating to the intervention 347 
pathway collected at Liverpool Women’s Hospital and St Mary’s Hospital will be analysed 348 
within the Liverpool Clinical Laboratories at the Royal Liverpool and Broadgreen University 349 
Hospital NHS Trust and the Manchester University NHS Foundation Trust, respectively.  350 
Additional samples that will be collected from both sites will be sent to the Centre for 351 
Women’s Health Research laboratories where they will be processed and stored until the 352 




































































In order to get the most information possible during the study period we will be asking 354 
women to allow us to use the remaining blood taken during PLANES to be used in other 355 
ethically approved research, a process called “gifting”. Since the initial application of the 356 
PLANES study, other companies have begun to produce PlGF biomarker tests (Perkin-Elmer 357 
and Quidel) and we will perform post-hoc analysis of blood samples with these companies to 358 
ascertain whether they could be used in the future management of SGA.  Neither of these 359 
tests will however be used to determine clinical care pathway during the study period. 360 
Data Management 361 
Study data will be captured using electronic case report forms (eCRFs) transcribed to a 362 
bespoke study database with participants identified only by their unique participant 363 
identification number allocated at randomisation. It will be accessed via a secure webpage 364 
by delegated research site staff and is designed and maintained by the LCTU. All eCRF data 365 
entered into the study database will be centrally monitored by the Centre for Women’s 366 
Health Research to ensure that data collected is consistent with adherence to the study 367 
protocol.  The database also includes validation features which will alert the user to certain 368 
inconsistent or missing data on data entry and if any problems are identified via automated 369 
validation or central monitoring, a query is raised and emailed to site.  Regular reports will be 370 
generated to identify discrepancies in the data, and allow for follow up. Electronic and paper 371 
screening logs will also be kept in clinics to record the number of patients declining 372 
participation and when volunteered the reason given, all of which will be kept in a secure 373 
locked location on NHS premises. 374 
Statistical Analysis 375 
Analysis of study data will take place once all participants have received the planned follow-376 
up and all data is available. The likelihood of missing data is small given the standard 377 




































































on a complete-case basis with no adjustments made (e.g. multiple imputation) in the case of 379 
missing data.  380 
A statistical analysis plan will be determined and finalised prior to final data lock. As the 381 
analyses being carried out are based on feasibility, the details in terms of the methodology 382 
may be altered during the course of the study. Patients will be summarised on an intention to 383 
treat basis retaining all patients irrespective of any protocol deviations.  Further secondary 384 
analysis will be carried out on a per protocol population.  Further analyses may be carried out 385 
on planned subgroups (e.g. those who meet the inclusion criteria for a future study) as is 386 
required. Multivariate data analysis techniques will be also used to attempt to find natural 387 
groupings in the generated data including hierarchical cluster analysis and principle 388 
component analysis. As this is an exploratory study no formal levels of significance are set.  389 
All statistics presented will be presented alongside 95% confidence intervals so as to give an 390 
indication of the level of precision only. Continuous data will be summarised as median, 391 
inter-quartile range (IQR) and ranges and categorical data shall be summarised as 392 
frequencies of counts and associated percentages. Quantitative analysis will involve simple 393 
descriptive statistics and the chi-square test for trend.  Data from each method will be 394 
analysed separately then synthesised through the use of constant comparative analysis. 395 
Perspectives Work Package  396 
The perspectives work package will include clinicians involved in PLANES as well as 397 
women, and their partners, who have provided consent to be contacted during enrolment 398 
into the PLANES study. Questionnaires and interviews will involve women in both the 399 
concealed and revealed pathways as well as those who declined randomisation. This will 400 
allow for meaningful exploration of different experiences on the approach to recruitment in 401 
the PLANES study, consent, decision making and length and content of trial information 402 
materials. Each patient and their partner (if applicable) will be provided with the PLANES 403 




































































applicable) to arrange an interview within approximately one month of consent. All interviews 405 
will be conducted using the PLANES women and partner interview topic guide which has 406 
been informed by previous pilot trials within the NHS and respondent validation will be used 407 
so previously unanticipated topics can be added as analyses progress [64,65]. The 408 
University of Liverpool PLANES Qualitative study team will conduct all focus groups and 409 
interviews. Interviews will be conducted until data saturation point; this is anticipated to be 410 
15-25 interviews and approximately 50 questionnaires (48% response rate). 411 
Clinicians involved in the PLANES study will be sent an email invitation to participate in a 412 
focus group at the end of the PLANES study recruitment period. The focus group 413 
(approximately 8-10 participants) will incorporate the use of voting software so that both 414 
qualitative and quantitative data are collected. All focus groups and interviews will be 415 
conducted using the clinician focus group and interview topic guides which will be informed 416 
by interim findings from women and birth partner questionnaires and interviews. Those 417 
unable to attend the focus group will be invited to participate in an interview and an online 418 
questionnaire.   419 
Thematic analysis of qualitative data from the interviews, questionnaires and focus groups 420 
will be assisted using NVivo 10 qualitative data analysis package and SPSS software for 421 
statistical analysis. Whilst data will be analysed thematically the focus will be modified to fit 422 
with the criterion of catalytic validity, whereby findings should be relevant to future research 423 
and practice (in particular, insight into trial acceptability and the design of the potential 424 
definitive RCT) [66,67].   425 
Health economic analyses 426 
By performing sFlt-1/PlGF ratio on women with SGA babies, we hope to be able to reduce 427 
the likelihood of intervention in those with a normal result, in turn reducing the number of 428 
preterm and early term deliveries and associated neonatal care. In those with abnormal 429 




































































the outcomes for these high-risk pregnancies. All of these outcomes have important cost 431 
implications that that would need further, comprehensive assessment in a larger definitive 432 
trial. 433 
The overarching aim of the economic analysis embedded in this study is to assess the 434 
feasibility of collecting relevant information on key economic outcomes.  Such outcomes 435 
include health care resource use (e.g. care related to birth and complications, cost of 436 
additional diagnostic tests) and relevant structured quantitative outcomes, related to 437 
childbirth experience and maternal health-related quality of life.  Childbirth experience will be 438 
captured through the use of the Childbirth Experience Questionnaire administered shortly 439 
after delivery [68, 69].  Quality of life will be collected through the widely used EuroQol 5D-5L 440 
instrument, which will be administered before and after delivery [70].  The quality and 441 
completeness of the collected data will be assessed and findings will inform data collection 442 
methods and schedules in the subsequent RCT.  443 
Trial Governance 444 
The PLANES study will have a Trial Management Group (TMG), Trial Steering Committee 445 
(TSC) and an Independent Safety and Data Monitoring Committee (ISDMC) to monitor the 446 
study progress. 447 
The TMG will be responsible for the day-to-day running and management of the study and 448 
will be comprised of the CI and other lead investigators / core study management staff. The 449 
TSC will provide oversight of the study, concentrating on progress of the study, adherence 450 
to protocol, participant’s safety and consideration of new information, making 451 
recommendations on study pathway modifications and continuation of the study. 452 
The ISDMC will be responsible for reviewing and assessing recruitment, interim monitoring 453 
of safety and effectiveness, trial conduct and external data.  A sub-committee will also meet 454 




































































as SAEs and to provide ongoing review of AE’s. The ISDMC will also provide 456 
recommendations to the TSC concerning continuation of the study. 457 
 458 
Discussion 459 
PLANES will assess the ability to modify the care of women carrying a SGA fetus at late 460 
preterm and term gestations using the placental biomarker sFlt-1/PlGF ratio with the aim of 461 
safely delaying delivery to a later gestation than currently advocated. The PLANES study will 462 
provide data on the acceptability of this management to participants and clinicians as well as 463 
the cost implications of the proposed intervention, both of which are important in determining 464 
if a larger RCT is feasible. The results from this study will be used to inform a future large 465 
randomised controlled trial investigating the effectiveness and cost-effectiveness of sFlt-466 
1/PlGF led management of SGA fetuses, powered for adverse pregnancy outcome.  467 
It is evident that more research is needed into the optimal management and timing of 468 
delivery of an SGA fetus. The current blanket approach by the RCOG [18] and many other 469 
national guidelines may reduce the risk of term stillbirth, however this comes at the detriment 470 
of a large proportion of SGA pregnancies undergoing early term deliveries who may not 471 
have needed this intervention and may increase the long term risks from earlier delivery 472 
which could have been avoided. Biomarkers for placental function may hold the key to 473 
identifying those pregnancies truly at risk of adverse outcomes, allowing for individualised 474 
care and reduction in intervention, however at present there is insufficient evidence to make 475 
a judgement regarding the efficacy of this approach [71]. Initial studies of the implementation 476 
of sFlt-1/PlGF ratio suggest that using biomarkers to determine requirement for or the timing 477 
of intervention is feasible [72]. More research and intervention trials in this area will not only 478 
address the priorities identified in the recent Saving Babies Lives Care Bundle but will help 479 
further develop guidance on the management of the SGA fetus [36]. 480 




































































Trial registration: ISRCTN REFERENCE: 58254381 482 
Protocol Version 2.0 7th August 2019 483 
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